Ceramide is generated by the hydrolysis of membrane sphingomyelin by sphingomyelinase and is implicated in multiple signaling pathways, including those regulating differentiation, inflammation and immune responses. Excess formation of prostaglandin E
2 (PGE
2) is thought to increase susceptibility to infection, rheumatoid arthritis and inflammation, including periodontal diseases. We investigated the inhibitory effect of C
2-ceramide, a short-chain ceramide analog, on the PGE
2-stimulated accumulation of cAMP in human gingival fibroblasts. In human gingival fibroblasts pre-treated with C
2-ceramide for 18 h, the PGE
2-stimulated accumulation of cAMP was reduced, but an inactive C
2-ceramide analog had no such effect. The accumulation of cAMP induced by EP2 and EP4 receptor agonists (ONO-AE1-259 and ONO-AE1-329, respectively) was inhibited in cells treated with C
2-ceramide. However, treatment with C
2-ceramide had no effect on the expression of mRNAs encoding the EP2 and EP4 receptors. Accumulation of cAMP could be induced by cAMP-elevating agents (forskolin, isobutylmethylxanthine and mastparan) but was not reduced by treatment with C
2-ceramide. These observations suggest that C
2-ceramide attenuates PGE
2 receptor function and consequently inhibits the accumulation of cAMP in human gingival fibroblasts.
抄録全体を表示